Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3678017, 10 pages
https://doi.org/10.1155/2017/3678017
Research Article

Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation

1Division of Clinical Laboratory Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
2Institute of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
3Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Correspondence should be addressed to Zsuzsa Bagoly; uh.bedinu.dem@ylogab

Received 13 February 2017; Revised 12 May 2017; Accepted 24 May 2017; Published 21 June 2017

Academic Editor: Christof Kolb

Copyright © 2017 Noémi Klára Tóth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Friberg, N. Hammar, and M. Rosenqvist, “Stroke in paroxysmal atrial fibrillation: report from the Stockholm cohort of atrial fibrillation,” European Heart Journal, vol. 31, no. 8, pp. 967–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Freestone and G. Y. Lip, “The endothelium and atrial fibrillation. The prothrombotic state revisited,” Hamostaseologie, vol. 28, no. 4, pp. 207–212, 2008. View at Google Scholar · View at Scopus
  3. F. L. Li-Saw-Hee, A. D. Blann, D. Gurney, and G. Y. H. Lip, “Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation: effects of cardioversion and return of left atrial function,” European Heart Journal, vol. 22, no. 18, pp. 1741–1747, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Feng, R. B. D'Agostino, H. Silbershatz et al., “Hemostatic state and atrial fibrillation (The Framingham Offspring Study),” American Journal of Cardiology, vol. 87, no. 2, pp. 168–171, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. G. H. Lip, “Does atrial fibrillation confer a hypercoagulable state?” The Lancet, vol. 346, no. 8986, pp. 1313-1314, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. T. E. Lackner and G. N. Battis, “Use of warfarin for nonvalvular atrial fibrillation in nursing home patients,” Archives of Family Medicine, vol. 4, no. 12, pp. 1017–1026, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Wu, S. Tong, Y. Xiang et al., “Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression,” PLoS ONE, vol. 10, no. 4, article e0124716, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Marín, V. Roldán, and G. Y. H. Lip, “Fibrinolytic function and atrial fibrillation,” Thrombosis Research, vol. 109, no. 5-6, pp. 233–240, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Drabik, P. Wołkow, and A. Undas, “Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: Association with thrombin generation, endothelial injury and platelet activation,” Thrombosis Research, vol. 136, no. 2, pp. 408–414, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Danese, M. Montagnana, G. Cervellin, and G. Lippi, “Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence,” Annals of Medicine, vol. 46, no. 6, pp. 364–371, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Kornej, B. Dinov, A. D. Blann et al., “Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von willebrand factor and IL-6 in the peripheral and cardiac circulation,” PLoS ONE, vol. 9, no. 11, article 0111760, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Galea, M. T. Cardillo, A. Caroli et al., “Inflammation and C-reactive protein in atrial fibrillation: cause or effect?” Texas Heart Institute Journal, vol. 41, no. 5, pp. 461–468, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Asakura, S. Hifumi, H. Jokaji et al., “Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation,” Blood Coagulation & Fibrinolysis, vol. 3, no. 4, pp. 469–473, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Mondillo, L. Sabatini, E. Agricola et al., “Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation,” International Journal of Cardiology, vol. 75, no. 2-3, pp. 227–232, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Hatzinikolaou-Kotsakou, Z. Kartasis, D. Tziakas et al., “Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?” Journal of Thrombosis and Thrombolysis, vol. 16, no. 3, pp. 155–161, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. R. Kahn, S. Solymoss, and K. M. Flegel, “Nonvalvular atrial fibrillation: Evidence for a prothrombotic state,” CMAJ, vol. 157, no. 6, pp. 673–681, 1997. View at Google Scholar · View at Scopus
  17. V. Roldan, F. Marin, P. Marco, J. G. Martinez, R. Calatayud, and F. Sogorb, “Hypofibrinolysis in atrial fibrillation,” American Heart Journal, vol. 136, no. 6, pp. 956–960, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. T.-D. Wang, W.-J. Chen, S. S. Y. I. Su et al., “Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism,” Journal of Cardiovascular Electrophysiology, vol. 12, no. 8, pp. 877–884, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Mitusch, H. J. Siemens, M. Garbe, T. Wagner, A. Sheikhzadeh, and K. W. Diederich, “Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy,” Thrombosis and Haemostasis, vol. 75, no. 2, pp. 219–223, 1996. View at Google Scholar · View at Scopus
  20. M. K. Freynhofer, D. F. Draxler, S. C. Gruber et al., “Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation,” Journal of Thrombosis and Haemostasis, vol. 11, no. 6, pp. 1069–1077, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. R. Kahn, S. Solymoss, and K. M. Flegel, “Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation,” CMAJ, vol. 157, no. 6, pp. 685–689, 1997. View at Google Scholar · View at Scopus
  22. K. Ohara, H. Inoue, T. Nozawa et al., “Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation,” International Journal of Cardiology, vol. 126, no. 3, pp. 316–321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. W. M. Feinberg, E. Macy, E. S. Cornell et al., “Plasmin-alpha2-antiplasmin complex in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators,” Thromb Haemost, vol. 82, pp. 100–103, 1999. View at Google Scholar
  24. J. G. Akar, W. Jeske, and D. J. Wilber, “Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction,” Journal of the American College of Cardiology, vol. 51, no. 18, pp. 1790–1793, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. R. Willoughby, R. L. Roberts-Thomson, H. S. Lim et al., “Atrial platelet reactivity in patients with atrial fibrillation,” Heart Rhythm, vol. 7, no. 9, pp. 1178–1183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Motoki, T. Tomita, K. Aizawa et al., “Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period - Comparison with chronic atrial fibrillation,” Circulation Journal, vol. 73, no. 8, pp. 1403–1407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. Z.-Q. Luo, X.-H. Hao, J.-H. Li, J. Dai, K.-Y. Liu, and Y.-Q. Lai, “Left atrial endocardial dysfunction and platelet activation in patients with atrial fibrillation and mitral stenosis,” Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 5, pp. 1970–1976, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. C. D. Schultz, G. Rangneker, H. S. Lim et al., “Characterization of thrombogenic, endothelial and inflammatory markers in supraventricular tachycardia: A study in patients with structurally normal hearts,” Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 8, pp. 551–557, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Patti, V. Pengo, R. Marcucci et al., “The left atrial appendage: from embryology to prevention of thromboembolism,” European Heart Journal, vol. 38, no. 12, pp. 877–887, 2016. View at Publisher · View at Google Scholar
  30. K. Wasmer and L. Eckardt, “Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines,” Europace, vol. 13, no. 10, pp. 1368–1374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Nagy-Baló, D. Tint, M. Clemens et al., “Transcranial measurement of cerebral microembolic signals during pulmonary vein isolation: a comparison of two ablation techniques,” Circulation: Arrhythmia and Electrophysiology, vol. 6, no. 3, pp. 473–480, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Kiss, E. Nagy-Baló, G. Sándorfi, I. Édes, and Z. Csanádi, “Cerebral microembolization during atrial fibrillation ablation: Comparison of different single-shot ablation techniques,” International Journal of Cardiology, vol. 174, no. 2, pp. 276–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Karpati, B. Penke, E. Katona, I. Balogh, G. Vamosi, and L. Muszbek, “A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma,” Clinical Chemistry, vol. 46, no. 12, pp. 1946–1955, 2000. View at Google Scholar · View at Scopus
  34. A. Alonso, W. Tang, S. K. Agarwal, E. Z. Soliman, A. M. Chamberlain, and A. R. Folsom, “Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study,” International Journal of Cardiology, vol. 155, no. 2, pp. 217–222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Freestone, F. Gustafsson, A. Y. Chong et al., “Influence of atrial fibrillation on plasma von Willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure,” Chest, vol. 133, no. 5, pp. 1203–1208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. D. S. G. Conway, L. A. Pearce, B. S. P. Chin, R. G. Hart, and G. Y. H. Lip, “Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation,” Circulation, vol. 107, no. 25, pp. 3141–3145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Gustafsson, M. Blomback, M. Britton, A. Hamsten, and J. Svensson, “Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation,” Stroke, vol. 21, no. 1, pp. 47–51, 1990. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Ko, J. W. Magnani, and E. M. Hylek, “Biomarkers in lone atrial fibrillation-an additional ‘fine tuning’ of risk?” Current Pharmaceutical Design, vol. 21, no. 5, pp. 646–658, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Y. Chong, G. Y. H. Lip, B. Freestone, and A. D. Blann, “Increased circulating endothelial cells in acute heart failure: comparison with von Willebrand factor and soluble E-selectin,” European Journal of Heart Failure, vol. 8, no. 2, pp. 167–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. D. S. G. Conway, L. A. Pearce, B. S. P. Chin, R. G. Hart, and G. Y. H. Lip, “Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors,” Circulation, vol. 106, no. 15, pp. 1962–1967, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Scridon, N. Girerd, L. Rugeri, E. Nonin-Babary, and P. Chevalier, “Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients,” Europace, vol. 15, no. 11, pp. 1562–1566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. K. M. Valentijn, J. E. Sadler, J. A. Valentijn, J. Voorberg, and J. Eikenboom, “Functional architecture of Weibel-Palade bodies,” Blood, vol. 117, no. 19, pp. 5033–5043, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Yamada and G. N. Kay, “Catheter ablation of atrial fibrillation in the elderly,” Pacing and Clinical Electrophysiology, vol. 32, no. 8, pp. 1085–1091, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. R. A. Winkle, R. H. Mead, G. Engel, M. H. Kong, and R. A. Patrawala, “Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban,” Europace, vol. 16, no. 10, pp. 1443–1449, 2014. View at Publisher · View at Google Scholar · View at Scopus